ASCO Launches Online Educational Initiative: ‘Grand Rounds’

Publication
Article
OncologyONCOLOGY Vol 14 No 7
Volume 14
Issue 7

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource-ASCO Grand Rounds- for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource—ASCO Grand Rounds— for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will be conducted by leading oncologists and cancer-care professionals and will include a physician-moderated online question-and-answer session for ASCO members. This new resource is available from ASCO OnLine, at www.asco.org.

Staying Current

ASCO Grand Rounds offers physicians an easy way to stay abreast of developments in cancer research. Each lecture consists of a 20- to 45-minute discussion that participants can listen to while viewing a synchronized slide presentation. Lectures will cover topics such as new drug development, cancer genetics, and supportive care and will be available throughout the year on ASCO’s website. Approximately two new lectures will be presented each month.

“We are excited that ASCO is taking a leading role in providing online education to oncologists around the world,” said ASCO president Joseph S. Bailes, MD.

Articles in this issue
Non–Small-Cell Lung Cancer Single-Agent Therapy
Linezolid-A New Option for Treating Gram-Positive Infections
Current Issues in the Treatment of Resistant Bloodstream Infections
Current Treatments for Infection in Neutropenic Patients With Hematologic Malignancy
Changing Patterns of Infections and Antimicrobial Susceptibilities
Ambulatory Antimicrobial Therapy for Hematologic Malignancies
Questions and Answers: Non–Small-Cell Lung Cancer
Questions and Answers: Small-Cell Lung Cancer
Irinotecan in Small-Cell Lung Cancer-Japanese Trials
Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC
Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
Extensive Small-Cell Lung Cancer: A Treatment Overview
Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Socazolimab Exhibits Overall Survival Benefit Vs Placebo in ES-SCLC

Roman Fabbricatore
June 7th 2025
Article

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan
June 5th 2025
Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.